Dr Susan Cleator, Consultant Clinical Oncologist

Dr Susan Cleator

Consultant Clinical Oncologist

Book online
|

Dr Susan Cleator BA BM Bch MRCP FRCR PhD

Consultant Clinical Oncologist

BA BM Bch MRCP FRCR PhD

Dr Susan Cleator

Consultant Clinical Oncologist BA BM Bch MRCP FRCR PhD

Book online
|
BA BM Bch MRCP FRCR PhD
HCA-Healthcare-UK

Areas of expertise

  • Breast cancer
  • Radiotherapy
  • Rectal cancer
  • Chemotherapy
  • Colorectal cancer
HCA-Healthcare-UK

Recommendations for Dr Cleator

These recommendations are for information purposes only. Doctors providing recommendations do so in good faith and are not responsible for clinical outcomes.

Recommended by:

  • byA GP

    Recommended oncologist

  • byA GP

    Recommended oncologist

  • byDr James Mackay, Consultant Clinical Genetic Oncologist

    Dr Susan Cleator is a specialist in breast cancer oncology.

  • byA GP

    Recommended oncologist

  • byA GP

    Recommended oncologist

  • byDr James Mackay, Consultant Clinical Genetic Oncologist

    Dr Susan Cleator is a specialist in breast cancer oncology.

  • Address

    • LOC at Chelsea

      102 Sydney Street, Chelsea, London, SW3 6NJ

    • LOC - Leaders in Oncology Care

      95-97 Harley Street, London, W1G 6AF

    • The Princess Grace Hospital

      42-52 Nottingham Place, London, W1U 5NY

    About Dr Susan Cleator

    GMC number: 3680629

    Year qualified: 1992

    Place of primary qualification: Oxford University

    Areas of expertise

    • Breast chemotherapy
    • Breast radiotherapy
    • Colorectal cancer chemotherpy
    • Colorectal radiotherapy
    • Anal cancer
    • Novel chemotherapy
    • Biological agents
    • General clinical oncology

    Professional memberships

    Royal College of Radiologists
    Royal College of Physicians
    General Medical Council

    Articles by Dr Susan Cleator

    Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (trec): a randomised, open-label feasibility study

    Systemic inflammatory response syndrome in a patient diagnosed with high grade inflammatory triple negative breast cancer: a case report of a potentially rare paraneoplastic syndrome

    The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis

    Clinical translation of [18f]icmt-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer

    Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy

    Cleator s, ashworth amolecular profiling of breast cancer: clinical implications. br j cancer 90: 1120-1124

    Ep-1199: cardiac dose delivered by left sided tumour bed electron boost; a potential source of toxicity

    Common variation near cdkn1a, pold3 and shroom2 influences colorectal cancer risk